BIGFOOT BIOMEDICAL CLOSES 36M IN SERIES “A” FINANCING
NOVO’s client, Bigfoot Biomedical, announced today a Series A investment of $35.5M to support its development of an automated insulin delivery system (sometimes referred to as an “artificial pancreas”)…